Monday, September 23, 2013

Cardiome Pharma Corp. - COM.t

Cardiome Pharma Corp. - COM.t is a research-based biopharmaceutical company dedicated to the development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide value to patients, physicians and healthcare systems. BrinavessTM (vernakalant IV), is approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

On September 17, 2013 the company released NEWS

"Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with Tzamal Medical Ltd., to sell and distribute BRINAVESS™ (vernakalant intravenous) exclusively in Israel. Under the terms of the agreement, Tzamal Medical has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement have not been disclosed.

“This agreement with Tzamal Medical reaffirms Cardiome’s commitment to continue making BRINAVESS available worldwide, including markets outside of Europe,” said Karim Lalji, Cardiome’s Chief Commercial Officer. “We are pleased to have partnered with an industry leader and look forward to leveraging Tzamal Medical’s expertise to commercialize BRINAVESS in the Israeli market.”